Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study
Author:
Affiliation:
1. UCB Pharma Slough UK
2. The Rockefeller University New York NY USA
3. Veramed London UK
4. UCB Pharma Braine‐l’Alleud Belgium
5. UCB Pharma Brussels Belgium
6. Institute of Pharmaceutical Science King’s College London London UK
Publisher
Wiley
Subject
Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20827
Reference33 articles.
1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis;Sbidian E;Cochrane Database Syst Rev,2020
2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
3. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
4. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
5. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of tumour necrotic factor‐α, interleukin‐17 and interleukin‐22 on the expression of filaggerin‐2 and hornerin: Analysis of a three‐dimensional psoriatic skin model;Skin Health and Disease;2024-09-05
2. Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy;Rheumatology and Therapy;2024-08-12
3. Generalized acrodermatitis continua of Hallopeau with an IL36RN variant successfully treated with bimekizumab;The Journal of Dermatology;2024-07-12
4. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials;Journal of the American Academy of Dermatology;2024-07
5. Burkholderia cepacia in cystic fibrosis children and adolescents: overall survival and immune alterations;Frontiers in Cellular and Infection Microbiology;2024-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3